These independent CME/CE activities are supported by an educational grant from Takeda Oncology.



Clinical Context:
Multiple Myeloma
  1. Curriculum III
  2. Curriculum II
  3. Curriculum I
  4. Full Course List
Chair
faculty image
Kenneth C. Anderson, MD
  • Kraft Professor of Medicine
  • Harvard Medical School
  • Director
  • Jerome Lipper Multiple Myeloma Center
  • Department of Medical Oncology
  • Dana-Farber Cancer Institute
  • Boston, Massachusetts

  • Clinical Context: Multiple Myeloma is designed to provide up-to-date information on patient identification, symptoms, risk factors, and current and emerging treatments and best practices in the management of multiple myeloma.

    The curriculum includes four case studies at the point of care and MedPage Today meeting coverage that will report on cutting-edge news as it breaks from the Society of Hematologic Oncology 2015 Annual Meeting, The European Cancer Congress 2015 Annual Meeting, European Society for Medical Oncology Summit Americas 2015, the 57th American Society of Hematology Annual Meeting & Exposition, and the 2016 American Society of Clinical Oncology Annual Meeting.
  • Describe the natural history of multiple myeloma, the importance of early diagnosis of this conidition, and recent advances in our understanding of pathophysiologic mechanisms that may serve as targets of therapy.
  • Evaluate criteria that have been developed to assess treatment response in multiple myeloma, delineate how these criteria can be used to risk-stratify patients in clinical practice, and consider therapeutic treatment options that improve patient outcomes.
  • Target Audience

    This series of activities is designed for hematologists, oncologists, radiologists, primary care physicians, internists, family practice practitioners, nurses, nurse practitioners, physician assistants, and pharmacists who treat patients with multiple myeloma.

     

    Activity Goal

    The goal of this program is to provide information and case studies at the point of care on current and emerging management strategies based on the most up-to-date evidence-based medicine and clinical trial results in multiple myeloma.